



Europad 
European Opioid Addiction Treatment Association **AU-CNS**
Per aspera ad astra Since 1994 Association for the Application of Neuroscientific Knowledge to Social Aims
World Federation for the Treatment of Opioid Dependence 
NGO with Special Consultative Status with United Nations Economic and Social Council (ECOSOC)
Affiliated to INTERNATIONAL SOCIETY OF ADDICTION MEDICINE

15th European Congress

Heroin Addiction & Related Clinical Problems

European Opioid Addiction Treatment Association - EUROPAD



May 20-22, 2022

Pisa, Italy, EU

**MACC (Meeting Art Craft Center)
P.za V. Emanuele II, 5**

www.europad.org; www.europadevents.org; www.heroinaddictionrelatedclinicalproblems.org

Europad



European Opioid Addiction Treatment Association

AU-CNS

Per aspera ad astra

Since 1994

Association for the
Application of
Neuroscientific Knowledge
to Social Aims

Affiliated to INTERNATIONAL SOCIETY OF ADDICTION MEDICINE

EUROPAD formerly EUMA was founded in Geneva (Switzerland) on September 26, 1994. It shall remain independent of political parties and of any government.

The vision

EUROPAD exists to improve the lives of substance non-medical users and their families and to reduce the impact of illicit drug use on society as a whole. The Association works to develop opioid addiction treatment in Europe but also aims to make a major contribution to the knowledge of, and attitudes to, addiction treatment worldwide.

Scientific Committee of Europad2022Pisa

Presidents

Icro Maremmani (Pisa, Italy)

Francesco Lamanna (Pisa, Italy)

Coordinators

Maurice Dematteis (Grenoble, France)

Andrej Kastelic (Ljubljana, Slovenia)

Marc Reisinger (Brussels, Belgium)

Lorenzo Somaini (Biella, Italy)

Local Scientific Committee

Angelo G. I. Maremmani (Viareggio, Italy)

Mario Miccoli (Pisa, Italy)

Matteo Pacini (Pisa, Italy)

Giulio Perugi (Pisa, Italy)

International Scientific Committee

Adrian-Octavian Abagiu (Bucarest, Romania)

Alexander Kantchelov (Sofia, Bulgaria)

Hannu Alho (Helsinki, Finland)

Evgeny Krupitsky (St. Petersburg, Russia)

Marc Auriacombe (Bordeaux, France)

Barbara Lovrecic (Ljubljana, Slovenia)

Alexander Baldacchino (St Andrews, Scotland, UK)

Mercedes Lovrecic (Ljubljana, Slovenia)

Itay Besser (Be'er Sheva, Israel)

Garrett McGovern (Dublin, Ireland)

Barbara Broers (Geneve, Switzerland)

Genci Mucullari (Tirana, Albania)

Miguel Casas (Barcelona, Spain)

Lubomir Okruhlica (Bratislava, Slovak Republic)

Thomas Clausen (Oslo, Norway)

Mark Parrino (New York, New York, USA)

Adrian Dunlop (Newcastle, Australia)

Luis Patricio (Lisbon, Portugal)

Michael Farrell (Sydney, New South Wales, Australia)

Einat Peles (Tel Aviv, Israel)

Loretta Finnegan (Satellite Beach, Florida, USA)

Jens Reimer (Hamburg, Germany)

Gabriele Fischer (Vienna, Austria)

Carlos Alonso Roncero (Salamanca, Spain)

Carla Gambarana (Siena, Italy)

Heino Stover (Frankfurt, Germany)

Gilberto Gerra (Parma, Italy)

Marta Torrens (Barcelona, Spain)

Edward Jacek Gorzelanczyk (Bydgoszcz, Poland)

Didier Touzeau (Paris, France)

Jovanovic Mirjana (Kragujevac, Serbia)

Albrecht Ulmer (Stuttgart, Germany)

Milazim Gjocaj (Pristina, Kosovo)

Peter Vossenbergh (Deventer, Netherlands)

Liljana Ignjatova (Skopje, Macedonia)

Stephan Walcher (Munich, Germany)

Under the Patronage of

World Federation for the Treatment of Opioid Dependence,
New York, NY, USA
*NGO with Special Consultative Status with United Nations
Economic and Social Council (ECOSOC)*

Promoted by

European Opioid Addiction Treatment Association,
Pisa, Italy, EU
Association for the Application of Neuroscientific Knowledge
to Social Aims,
Pietrasanta, Italy, EU
Pisa School of Experimental and Clinical Psychiatry,
Pisa, Italy, EU



EACCME

**European Accreditation Council for Continuing
Medical Education**

The 15th European Congress “Heroin Addiction and Related Clinical Problems”

Pisa, Italy, 20/05/2022-22/05/2022

has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®)

for a maximum of 21 European CME credits (ECMEC®S).

Organizing Committee

**Ti.Gi. Congress, Via Udine, 12 - 58100 GROSSETO, Italy
Phone +39 0564412038 - Fax +39 0564412485
E-mail: giusi@tigicongress.com**

**AU-CNS, Via XX Settembre, 83 - 55045 PIETRASANTA, LU, Italy
Phone +39 0584790073
E-mail: info@aucns.org**

Europad

European Opioid Addiction Treatment Association

Per aspera ad astra

Since 1994

Affiliated to INTERNATIONAL SOCIETY OF ADDICTION MEDICINE



AU CNS

Association for the Application
of Neuroscientific Knowledge
to Social Aims

Executive Committee

President



Icro Maremmi
(Italy)

Vice President



Marc Reisinger
(Belgium)

General Secretary



Andrej Kastelic
(Slovenia)



World Federation for the Treatment of Opioid Dependence

NGO with Special Consultative Status with United Nations Economic and Social Council (ECOSOC)

World Federation for the Treatment of Opioid Dependence Executive Committee

President



Icro Maremmi
(Italy)

Vice President



Mark W. Parrino
(USA)

Treasurer



Michael Rizzi
(USA)

Corporate Secretary




Marc Reisinger
(Belgium)

PROGRAM


FRIDAY MAY 20, 2022

TIME	ABSTRACT NO	
<div style="display: flex; align-items: center;"> ○ <h3>ORAL PRESENTATIONS</h3> </div>		
9:00 12:30	PLENARY	EUROPAD SELECTED ORAL PRESENTATIONS <i>Chair: Matteo Pacini (Pisa, Italy, EU)</i>
	OP-1	SHAHRAM NADERI MAZJIN (Tehran, Iran) - Oxytocin Combination with Group Therapy Modulates Withdrawal Symptoms and Cognitive Control after Methadone Cessation in Opioid Addicts: Evidence from FMRI Study
	OP-2	PIYUSH GOYAL (New Delhi, India) - Trazodone for Sleep Disturbance in Opioid Dependent Patients Maintained on Buprenorphine: A Double-Blind, Placebo-Controlled Trial
	OP-3	MAURICE DEMATTEIS (Grenoble, France, EU) - Respective Expectations and Representations of Drug Addicts and Community Pharmacists: It Is Time to Improve Academic Training for Pharmacy Students in France
	OP-4	SAMIR SHIMON KASPER (Zenica, Bosnia and Herzegovina, BA) - Sleep Disorders in Opiate Addicts Treated at the Detox Ward of the Institute for Addiction Diseases, Zenica 2011-2021. Therapeutic Potential of Opiate Agonists in the Treatment of Sleep Disorders
	OP-5	CAROLINE SCHMITT-KOOPMANN (Lausanne, Schweiz, CH) - Variation in Swiss Regulation of Opioid Agonist Treatment
	OP-6	FABIO CURCIO (Napoli, Italia, EU) - Epidemiological Data of Foreign Drug and Alcohol Addicted in Napoli, Italy
	OP-7	VINCENZA CONTURSO (Napoli, Italia, EU) - Role of the Serd in the Current Management of Viral Hepatitis B, Delta and C. The Experience of Serd 32 ASL Napoli 1 Center
	OP-8	ULMER ALBRECHT (Stuttgart, Deutschland, EU) - The Same Medication, Very Beneficial Here – So Dangerous There That It Seems to Be out of the Question. What Makes the Difference?
	OP-9	ADRIAN O. ABAGIU (Bucharest, Romania, EU) - Are Patients with Opioid Addiction Really “Protected” from SARS COV-2 Infections?
	OP-10	MICHELS INGO ILJA (Frankfurt, Deutschland, EU) - Developments in the Medication Assisted Treatment for Opioid Users in Central Asia and China: Barriers and Facilitators
<div style="display: flex; align-items: center;"> ○ <h3>EUROPAD PRE-CONGRESS SYMPOSIUM</h3> </div>		
10:30 12:00	ROOM A	PCS1 - ASSESSING HEROIN USE DISORDER PATIENTS <i>Chair: Mario Miccoli (Pisa, Italy, EU)</i>
	PCS1-1	ANDREA POLI (Pisa, Italia, EU) - Subtyping Patients with Heroin Addiction at Treatment Entry: Factors Derived from the SCL-90
	PCS1-2	MARIO MICCOLI & LORENZO TUMMINELLO (Pisa, Italia, EU) - The TALS – Reduced Form: An Inventory for Assessing the Heroin Post-Traumatic Stress Disorder Spectrum (H/PTSD-S)
	PCS1-3	FILIPPO DELLA ROCCA (Pisa, Italia, EU) - An Inventory for Assessing the Behavioural Covariates of Craving in Heroin Use Disorder Patients

FRIDAY MAY 20, 2022

TIME	ABSTRACT NO	
 EUROPAD PRE-CONGRESS SYMPOSIA		
13:00 14:30	PLENARY	PCS2 - GENDER DIFFERENCES IN ADDICTION AND ODT <i>Chair: Angelo G. I. Maremmanni (Viareggio, Italy, EU)</i>
	PCS2-1	MARTA TORRENS (Barcelona, Spain, EU) - Opioid use disorder: a gender perspective
	PCS2-2	GABRIELE FISCHER (Vienna, Austria, EU) - Are men more vulnerable than females?
	PCS2-3	BERNADETTE HARD (St. Mellons, Cardiff, UK) - How long-acting formulations can improve quality of life for women with Opioid Dependence
14:30 16:00	PLENARY	INDUSTRY-SPONSORED SYMPOSIUM - CME NOT ACCREDITED
16:00 17:00	PLENARY	PCS4 - MEET THE EXPERT <i>Chair: Icro Maremmanni (Pisa, Italy, EU)</i>
	PCS4-1	ANGELO G. I. MAREMMANI (Viareggio, Italy, EU) - Levomethadone: the evolution in the treatment of Opioid Use Disorder patients

FRIDAY MAY 20, 2022

TIME	ABSTRACT NO	
○ EUROPAD PLENARY SESSION		
	PLENARY	PLENARY 1 <i>Chairs: Icro Maremmani and Francesco Lamanna (Pisa, Italy, EU)</i>
17:15 17:30	PL-0	ICRO MAREMMANI (Pisa, Italy, EU) and FRANCESCO LAMANNA (Pisa, Italy, EU) - Conference opening
17:30 18:00	PL-1	MARK PARRINO (New York, NY, USA) - Opioid Pandemia in US - Countermeasures and Perspectives
18:00 19:00	PL-2	Sir JOHN STRANG (London UK) - Thomas de Quincey's - Confessions of an English Opium Eater - 200 years old but still fresh and relevant today
19:00 20:00	PL-3	MAURICE DEMATTEIS (Grenoble, France, EU) - Pain in Opioid Use Disorder patients: A Challenge for Patients and Healthcare Professionals
○ WELCOME COCKTAIL AND EUROPAD CHIMERA AWARD 2022		
20:00		THE ALESSANDRO TAGLIAMONTE AWARD <i>Chairs: Icro Maremmani (Pisa, Italy, EU), Marc Reisinger (Brussels, Belgium, EU) and Andrej Kastelic (Ljubljana, Slovenia, EU)</i>
		CHIMERA AWARD 2022
		TO BE AWARDED: HANNU ALHO (Helsinki, Finland)
		LILJANA IGNJATOVA (Skopje, North Macedonia)
		ADRIAN-OCTAVIAN ABAGIU (Bucharest, Romania, EU)
		CAREER AWARD: SIR JOHN STRANG (London, UK)
		 CHIMERA AWARD European Opiate Addiction Treatment Association Award <i>"The Alessandro Tagliamonte Award"</i>   "Dedicated to all those who dream of a better world for drug addicts"
		 ROVAI SCHOLARS AWARD PISA-School of Clinical and Experimental Psychiatry Association for the Application of Neuroscientific Knowledge to Social Aims (AU-CNS) <i>"The Luca Rovai Award"</i>   "Dedicated to all those who dream of a better world for drug addicts"
		Best poster Rovai Scholars award

CONCERT IN HONOUR OF ROBERT NEWMAN AND MARY JEANNE KREEK

*Robert-Newman-Trio, a composition of Albrecht Ulmer
Andrey Khvostenko, violin
Marcin Niziol, viola
Albrecht Ulmer, piano forte*

SATURDAY MAY 21, 2022

TIME	ABSTRACT NO	
○ EUROPAD SYMPOSIA		
8:30-10:00	PLENARY	S01 - COMBATING STIGMA AMONG OPIOID MAINTENANCE TREATMENT (OMT) PATIENTS <i>Chair: Welle-Strand Gabrielle (Oslo, Norway)</i>
	S01-1	GABRIELE FISCHER (Vienna, Austria, EU) - New Treatment Option Reduces Stigma
	S01-2	GABRIELLE WELLE-STRAND & MARIANNE PIERRON (Oslo, Norway) - How Do 861 Opioid Maintenance Treatment (OMT) Users in Norway Perceive the Treatment and Follow-up They Receive? To What Degree Can They Influence Their Own Treatment? A User-to-User Survey by Prolar Nett
	S01-3	FRANCINA FONSECA (Barcelona, Spain, EU) - The Use of New Synthetic Opioids in Spain. Detection of New Synthetic Opioids in Opioid Users in Spain
	ROOM A	S06 - OPIOIDS TREATMENT AND HARM REDUCTION POLICY IN ISRAEL <i>Chair: Marc Reisinger (Brussels, Belgium, EU)</i>
	S06-1	NADAV GORNO (Lev-Hasharon, Israel) - Treatment of Patients with Dual Diagnosis: Major Psychiatric Disorders and Addictions with Extended Release Sublocade
	S06-2	HAGIT BONNY-NOACH (Ramat Gan, Israel) - Harm Reduction Drug Policy in Israel: What Has and Still Needs to Be Accomplished?
	S06-3	MICHAEL AMNON (Tel-Hai, Israel) - Harm Reduction with Opioids Disorder: Policy and Success Factors
○ EUROPAD PLENARY SESSION		
10:00-11:00	PLENARY	PLENARY 2 <i>Chair: Marc Auriacombe (Bordeaux, France, EU)</i>
	PL-4	YIFRAH KAMINER (Farmington, CT, USA) - American Youth Intentional Drugs-Opioid Fatal Overdose: The Magnitude of the Problem & Improved Assessment of Intentionality
○ EUROPAD SYMPOSIA		
11:00-12:30	PLENARY	S02 - OPIOID AGONIST TREATMENT IN ALCOHOL USE DISORDER <i>Chair: Amine Benyamina (Paris, France, EU)</i>
	S02-1	MAURICE DEMATTEIS (Grenoble, France, EU) - Alcohol, from Use to Use Disorder, fromn Pleasure to Dysphoria: Which Opioidergic Modulation According to Patients and Stages of the Addiction Development?
	S02-2	ULMER ALBRECHT (Stuttgart, Germany, EU) - Experiences with Opioids as Treatment for Alcohol Use Disorder (AUD)
	S02-3	NAZZARENO CANNELLA (Camerino, Italy, EU) - Buprenorphine in alcohol use disorder: Beyond classical opioid receptors
11:00-12:30	ROOM A	S07 - OPIOID AGONIST TREATMENT OUTCOMES <i>Chair: Thomas Clausen (Oslo, Norway, EU)</i>
	S07-1	GUSTAVO SUGAHARA (Oslo, Norway) - Treatment Target and Self-Assessed Treatment Outcome among Patients in Opioid Maintenance Treatment (OMT)
	S07-2	THOMAS CLAUSEN (Oslo, Norway) - Treatment Satisfaction among Patients in Opioid Agonist Treatment (OAT); 12-Month Treatment Outcomes
	S07-3	MATTEO PACINI (Pisa, Italy, EU) - Monitoring Agonist Opioid Treatment Outcomes


SATURDAY MAY 21, 2022


TIME	ABSTRACT NO	
○ EUROPAD PLENARY SESSION		
12:30-13:30	PLENARY	PLENARY 3 <i>Chair: Jean-Pierre Daulouede (Bayonne, France, EU)</i>
	PL-5	WIM VAN DEN BRINK (Amsterdam, Netherlands) - ADHD and Opioid Addiction
○ LUNCH		
○ EUROPAD SYMPOSIA		
14:30-16:00	PLENARY	S03 - USE OF PSYCHIATRIC MEDICATIONS IN DUAL DISORDER HEROIN USE DISORDER PATIENTS <i>(in collaboration with World Association on Dual Disorder - WADD)</i> <i>Chair: Nestor Szerman (Madrid, Spain, EU)</i>
	S03-1	NESTOR SZERMAN (Madrid, Spain, EU) - Opioid system and mental disorders
	S03-2	ICRO MAREMMANI (Pisa, Italy, EU) - Use of psychiatric medications in dual disorder (heroin use disorder/mood disorders) patients
	S03-3	ANGELO G. I. MAREMMANI (Viareggio, Italy, EU) - Use of psychiatric medications in dual disorder (heroin use disorder/psychotic disorder) patients
	ROOM A	S08 - CASES OF ASSESSMENTS OF NATIONAL DRUG HEALTH PROBLEMS AND PUBLIC HEALTH MEASURES <i>Chair: Mercedes Lovrecic (Ljubljana, Slovenia, EU)</i>
	S08-1	MILAN KREK (Ljubljana, Slovenia, EU) - National Drug Strategy and Action Plan: Lessons and Challenges to Improve the Effectiveness of Dealing with Drug Problems
	S08-2	ADA HOCEVAR (Ljubljana, Slovenia, EU) - What Is Going On? Changing Patterns of Drug Use in Slovenia
	S08-3	MARJETKA JELENC (Ljubljana, Slovenia, EU) - Violence against Working Personnel in Slovenian Drug Addiction Treatment Centre Network
○ EUROPAD PLENARY SESSION		
16:00-17:00	PLENARY	PLENARY SESSION 4 - MEET THE EXPERTS <i>Chair: - Icro Maremmani (Pisa, Italy, EU)</i>
	PL-6	MICHAEL FROST (Conshohocken, PA, USA) & AUGUSTO CONSOLI (Torino, Italy, EU) - Buprenorphine implant: a better way to improve patients' QoL?
17:00-18:00	PLENARY	PLENARY SESSION 5 - MEET THE EXPERTS <i>Chair: Maurice Dematteis (Grenoble, France, EU)</i>
	PL-7	MARK PARRINO (New York, NY, USA, PA, USA) & KEN LEE (London, Canada) - Methadone vs. buprenorphine in fentanyl overdoses prevention
20:00		SPEAKERS' DINNER*
		* Tickets are available for all delegates

SUNDAY MAY 22, 2022

TIME	ABSTRACT NO	
○ EUROPAD SYMPOSIA		
8:30 10:00	PLENARY	S04 - NEW OPIOID AGONIST FORMULATIONS FOR THE TREATMENT OF OPIOID USE DISORDER AND PAIN <i>Chair: Lorenzo Somaini (Biella, Italy, EU) - Claudio Leonardi (Roma, Italy, EU)</i>
	S04-1	SALVATORE DE FAZIO (Brindisi, Italy, EU) - Advantages and Limitations of Current Therapies for Opioid Use Disorder
	S04-2	SARAH VECCHIO (Biella, Italy, EU) - New Agonist Opioid Formulations
	S04-3	SEBASTIANO MERCADANTE (Palermo, Italy, EU) - The Use of Methadone in Patients with Pain and Opioid Use Disorder
8:30 10:00	ROOM A	S09 - RECOVERING FROM OPIOID USE DISORDER: OLD PERILS, NEW PROMISES <i>Chair: Sharon Rabinovitz (Haifa, Israel)</i>
	S09-1	EVI ZIV (Netanya, Israel, IL) - Reflective Overview of Continuum of Care for Dual Diagnosis Opiate Addicted Persons in Israel
	S09-2	SHARON RABINOVITZ (Haifa, Israel, IL) - Exploring Recovery Capital in Stable Recovery from Substance Use Disorder
	S09-3	IGOR GORJALTSAN (Beer-Sheva, Israel, IL) - Beyond Harm Reduction: Sublocade Treatment Engagement Motivations and Effects
○ EUROPAD PLENARY SESSION		
10:00- 11:00	PLENARY	PLENARY 6 <i>Chair: Francesco Lamanna (Pisa, Italy, EU)</i>
	PL-8	ARI KASKI (Kuopio, Suomi, Finland, EU) - Survey among untreated high-risk opioid users explored reasons why they are not willing to seek opioid maintenance treatment in Finland

SUNDAY MAY 22, 2022

TIME	ABSTRACT NO	
 EUROPAD SYMPOSIA		
11:00-12:30	PLENARY	S05 - SEEANET SYMPOSIUM: LIASION MEDICINE AND OPIOID ADDICTION <i>Chair: Andrej Kastelic (Ljubljana, Slovenia, EU)</i>
	S05-1	NUSA SEGREC (Ljubljana, Slovenia, EU) - Liasion Psychiatry and Substance Abuse Part 1
	S05-2	MIRJANA DELIC (Ljubljana, Slovenia, EU) Liasion Psychiatry Part 2 - Practical Issues in Liasion Psychiatry for Addicted Persons- Experience from Slovenia
	S05-3	LILJANA IGNJATOVA (Skopje, North Macedonia) - Challenges Patients Face in an Opioid Agonist Maintenance Program in North Macedonia. How to Respond?
11:00-12:30	ROOM A	S10 - METHADONE-ASSISTED PSYCHOTHERAPY <i>Chair: Alexander Kantchelov (Sofia, Bulgaria, EU)</i>
	S10-1	TSVETANA STOYKOVA (Sofia, Bulgaria, EU) - Clinical Symptoms and Addiction: Psychotherapeutic Interventions
	S10-2	SILVIA FRANKE (Vienna, Austria, EU) - Psychotherapy with Opiate Addicted Clients and Change of Abstinence Paradigm
	S10-3	ALBRECHT ULMER (Stuttgart, Germany, EU) - Trust and Empathy as Key Elements in the Treatment of Addicted Patients
 EUROPAD PLENARY SESSION		
12:30-13:30	PLENARY	PLENARY 7 <i>Chair: Giulio Perugi (Pisa, Italy, EU)</i>
	PL-9	MARTA TORRENS (Barcelona, Spain, EU) - Psychopathology and Opioid Addiction
13:30-13:45	CLOSING REMARKS	ICRO MAREMMANI (Pisa, Italy, EU) - Closing remark and see you in Lisbon, Portugal, in May 24-26, 2024!

 POSTER SESSION	
P-01	FARAH B A A AL-DEWAISSAN (Strathclyde, Scotland, UK) - Prevalence of Suboptimal Dosing of Methadone and Buprenorphine and Associated Factors in Opioid Dependent Patients
P-02	VIJAY CHANDRAN (Los Angeles, CA, USA) - Psilocybin (Majic Mushroom) - Self-Medication Practices with Psychedelics
P-03	FABIO CURCIO (Napoli, Italy, EU) - Observational Study on the Therapeutic Efficacy of Levomethadone in Patients on Maintenance Treatment for Opioid Dependence. Two Years of Follow Up
P-04	DUDI GOLD (Tel Aviv, Israel) - Opioid Addiction Treatment: Alternatives to 12-Step Programmes for Adolescents
P-05	DUNCAN HILL (Glasgow, Scotland, UK) - Prevalence of Psychiatric and Physical Comorbidities in Patients Diagnosed with Opioid Use Disorder (OUD) in Lanarkshire, Scotland, 2018-2019: Cross-sectional Study
P-06	LUCIE PENNEL (Grenoble, France, EU) - Etape: An Educational and Therapeutic Program for Relatives of People Suffering from Addictions
P-07	MARIA RITA QUARANTA (Martina Franca, Italy, EU) - Opioid Use Disorder and Opioid Agonist Treatment: Evolution of a Treatment Path. From Buprenorphine/ Naloxone Sublingual Tablets to Film. Experience of SERD (NHS Public Services for Pathological Addictions) in Martina Franca (TA), Italy
P-08	MARIA RITA QUARANTA (Martina Franca, Italy, EU) - Systematic Hcv Screening and Search for the Submerged in the Experience of the SERD (NHS Public Services for Pathological Addictions) in Martina Franca (TA), Italy
P-09	MARCO RIGLIETTA (Bergamo, Italy, EU) - Early Experience with Bup/Nal Sublingual Film in Northern Italy. Differences and Similarities between Custodial and Community Settings and Case-Reports
P-10	MARKUS PARTANEN (Turku, Suomi, Finland, EU) - Early Experience of Buprenorphine Long-Acting Injection in Finland: A Retrospective Cohort Study
P-11	LEV SHAGAL (Hadera, Israel) - An Overview of Covid19 Pandemic Impact over the Use of Opioids among Youth in Israel and the Treatment Challenges
P-12	AVIVA WOLF (Tzur Moshe, Israel) - Implementation of Sublocade Induction Protocol Amongst Smi-Severe Mental Illness Patients in the Dual Diagnosis Ward Lev-Hasharon Medical Center – Israel
P-13	DORIT YODASHKIN PORAT (Kfar Saba, Israel) - Peddy - a Case Report of Opioid Addiction in an Israeli Youngster During Covid 19 Epidemic

INDUSTRY-SPONSORED SYMPOSIUM - CME NOT ACCREDITED

FRIDAY MAY 20, 2022

14:30 16:00	PLENARY	PCS3 - INTRODUCING BUP/NAL FILM TO PATIENTS. A MULTIDISCIPLINARY VIEW <i>Chair: Duncan Hill (Glasgow, Scotland, UK)</i>
	PCS3-1	DUNCAN HILL (Glasgow, Scotland, UK) - Bup/Nal tablets vs film: does formulation result in a clinical difference?
	PCS3-2	JEN VANDUSEN (Kingston, Ontario, Canada) - Bup/Nal Film in Canadian Prison – a Nurse Perspective
	PCS3-3	JOSE CRUANES (Lund, Sweden, EU) - Experience of Bup/Nal Film in Sweden

FACULTY

ADRIAN O. ABAGIU	National Institute for Infectious Diseases Prof. Dr. Matei Bals - ARENA OST Center, Bucharest, România, EU
FARAH B A A AL-DEWAISSAN	University of Strathclyde, Scotland, UK
MICHAEL AMNON	Haderech Center and Tel-Hai Academic College, Tel-Hai,
MARC AURIACOMBE	Department of Psychiatry and Addictions, University of Bordeaux, Bordeaux, France, EU
AMINE BENYAMINA	Center for Education, Research and Treatment of Addictions, Paris Sud University Hospital, Paris, France, EU
HAGIT BONNY-NOACH	Ariel University & Board Member of Israeli Society of Addiction Medicine (ILSAM), Ramat Gan, Israel
NAZZARENO CANNELLA	University of Camerino, Camerino, Italy, EU
VIJAY CHANDRAN	UCLA VA Addiction Program, Los Angeles, CA, USA, Los Angeles, CA, USA
THOMAS CLAUSEN	SERAF, Norwegian Centre of Addiction Research, Oslo, Norway
AUGUSTO CONSOLI	Department of Addiction Medicine, Torino, Italy, EU <i>[Retired]</i>
VINCENZA CONTURSO	SERD DS32 ASL Napoli 1 Centro, Napoli, Italia, EU
JOSE CRUANES	Läkare at Region Skåne, Lund, Sweden, EU
FABIO CURCIO	ASL Napoli 1 Centro - Dipartimento Dipendenze - U.O.C. Dipendenze Ovest, Napoli, Italia, EU, Napoli, Italia, EU
JEAN-PIERRE DAULOUEDE	Côte Basque Hospital, Bayonne, France, EU
SALVATORE DE FAZIO	Department of Addiction Medicine, Brindisi, Italy, EU
MIRJANA DELIC	Center for Treatment of Drug Addiction, University Psychiatric Clinic, Ljubljana, Slovenia, EU
FILIPPO DELLA ROCCA	School of Psychiatry, University of Pisa, Pisa, Italy, EU
MAURICE DEMATTEIS	Grenoble Alpes University Hospital, Grenoble, France, EU
GABRIELE FISCHER	Addiction Clinic, Vienna, Austria, EU
FRANCINA FONSECA	Addiction Research Group (GRAd), Neuroscience Research Program, Hospital del Mar Medical Research Institute, Barcelona, Spain, EU
SILVIA FRANKE	Vienna, Austria, EU
MICHAEL FROST	Frost Medical Group, Conshohocken, PA, USA
DUDI GOLD	Gold Center, Tel Aviv, Israel
IGOR GORJALTSAN	School of Criminology, Faculty of Law and The Unit for Excellence in Research & Study of Addiction (ERSA), University of Haifa, Beer-Sheva, Israel
NADAV GORNO	Dual Diagnosis Ward, Lev-Hasharon Medical Center, Lev-Hasharon,
PIYUSH GOYAL	Senior Resident (Ex), New Delhi, India
BERNADETTE HARD	Kaleidoscope, St. Mellons, Cardiff, UK
DUNCAN HILL	NHS Lanarkshire, Addiction Services, Motherwell, Scotland, UK, Glasgow, Scotland, UK
ADA HOCEVAR	National Institute of Public Health, Ljubljana, Slovenia, EU
LILJANA IGNJATOVA	Faculty of Medicine, Department for Psychiatry, Skopje, North Macedonia

MICHELIS INGO ILJA	Frankfurt University of Applied Sciences, Frankfurt Institute of Drug Research, Frankfurt, Germany, EU
MARJETKA JELENC	National Institute of Public Health, Ljubljana, Slovenia, EU
YIFRAH KAMINER	Professor Emeritus of Psychiatry & Pediatrics, University of Connecticut School of Medicine, Farmington, CT, USA
ALEXANDER KANTCHELOV	Kantchelov Clinic, Sofia, Bulgaria, EU
ARI KASKI	Päihdepalvelusäätiö, Kuopio, Suomi, EU, Kuopio, Suomi, EU
SAMIR SHIMON KASPER	Inpatient Department in Cantonal Institute of Addiction, Zenica, Bosnia and Herzegovina
ANDREJ KASTELIC	Center for Treatment of Drug Addiction, University Psychiatric Clinic, Ljubljana, Slovenia, EU
MILAN KREK	National Institute of Public Health, Ljubljana, Slovenia, EU
FRANCESCO LAMANNA	Department of Addiction Medicine, ASL North-West Tuscany, Pisa, Italy, EU
KEN LEE	London RAAM Clinic, London, Canada
CLAUDIO LEONARDI	Department of Addiction Medicine, Roma, Italy, EU
MERCEDES LOVRECIC	National Institute of Public Health, Ljubljana, Slovenia, EU
ANGELO G. I. MAREMMANI	Department of Psychiatry, North-Western Tuscany Region NHS Local Health Unit, Viareggio, Italy, EU
ICRO MAREMMANI	Professor of Addiction Medicine, University of Pisa, Italy, EU and UniCamillus, International Medical University in Rome
SEBASTIANO MERCADANTE	La Maddalena, Department of Oncology, Palermo, Italy, EU
MARIO MICCOLI	Department of Experimental and Clinical Medicine, University of Pisa, Pisa, Italy, EU
SHAHRAM NADERI MAZJIN	Phd of Addiction Study, Medical University Tehran, Tehran, Iran
MATTEO PACINI	V. P. Dole Research Group, G. Delisio Institute of Behavioural Sciences, Pisa, Italy
MARK PARRINO	AATOD, New York, NY, USA
MARKUS PARTANEN	A-Clinic Ltd., Turku, Suomi, Finland, EU
LUCIE PENNEL	Department of Addiction Medicine, University Hospital of Grenoble, Grenoble, France, EU
GIULIO PERUGI	Department of Experimental and Clinical Medicine, University of Pisa, Pisa, Italy, EU
MARIANNE PIERRON	proLAR NETT, Sogne, Norway
ANDREA POLI	Department of Clinical and Experimental Medicine, Pisa, Italia, EU
MARIA RITA QUARANTA	Department of Addiction Medicine - ASL Taranto, Martina Franca, Italia, EU
SHARON RABINOVITZ	School of Criminology, Faculty of Law and The Unit for Excellence in Research & Study of Addiction (ERSA), University of Haifa, Haifa, Israel
MARC REISINGER	EUROPAD, Brussels, Belgium, EU
MARCO RIGLIETTA	UO Dipendenze - ASST Papa Giovanni XXIII, Bergamo, Italy, EU, Bergamo, Italia, EU
CAROLINE SCHMITT-KOOPMANN	Service of Addiction Medicine, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Schweiz

NUSA SEGREC	Center for Treatment of Drug Addiction, University Psychiatric Clinic, Ljubljana, Slovenia, EU
LEV SHAGAL	Lev Hasharon Mental Health Center Tel Aviv University, Hadera, Israel
LORENZO SOMAINI	Department of Addiction Medicine, Biella, Italy, EU
TSVETANA STOYKOVA	Kanthchelov, Alexander, Sofia, Bulgaria, EU
JOHN SIR STRANG	King's College London, London, UK
GUSTAVO SUGAHARA	SERAF UiO and ARA-SSHF, Oslo, Norge
NESTOR SZERMAN	Complutense University, Madrid, Spain, EU
MARTA TORRENS	“Del Mar” Hospital, University of Barcelona, Spain, EU, Barcelona, Spain, EU
TUMMINELLO LORENZO	Department of Experimental and Clinical Medicine, University of Pisa, Pisa, Italy, EU
ALBRECHT ULMER	Institute for Addiction Research, Stuttgart, Deutschland, EU
WIM VAN DEN BRINK	Professor Emeritus of Addiction Medicine, Amsterdam, The Netherlands, EU
JENN VANDUSEN	Correctional Service of Canada, Kingston, Ontario, Canada
SARAH VECCHIO	Department of Addiction Medicine, Biella, Italy, EU
GABRIELLE WELLE-STRAND	Norwegian Centre of Addiction Research, Oslo, Norway
AVIVA WOLF	Lev-Hasharon Medical Center, Tzur Moshe, Israel, IL
DORIT YODASHKIN PORAT	Lev Hasharon Mental Health Center, Tel Aviv University, Kfar Saba, Israel
EVI ZIV	School of Criminology, Faculty of Law and The Unit for Excellence in Research & Study of Addiction (ERSA), University of Haifa, Netanya, Israel



ROVAI SCHOLARS AWARD

PISA-School of Clinical and Experimental Psychiatry
Association for the Application of Neuroscientific Knowledge to Social Aims (AU-CNS)

"The Luca Rovai Award"



"Dedicated to all those who dream of a better world for drug addicts"

Rovai Scholars award, named after one of the founding member of PISA-School of Experimental and Clinical Psychiatry Dr. Luca Rovai is a prestigious title in the field of Psychiatry and Addiction Medicine granted by the PISA-School of Experimental and Clinical Psychiatry and the Association for the Application of Neuroscientific Knowledge to Social Aims (AU-CNS) to a select group of promising residents in Psychiatry and Addiction Medicine and young specialists in these fields.

FORMER RECIPIENTS:

From Intense to Occasional Use of Cocaine in Dual Disorder (ADHD/Cocaine Use Disorder) Patients Treated with Stimulant Medications by **C. Manni, A. Palluchini, G. Cipollone, V. Spera, M. Maiello, M. Novi, G. Perugi and I. Maremmani**. Poster presented at *New paradigms for mental disorders: Neurodevelopmental, neuroprogressive and neurodegenerative perspectives* Pisa, Italy, October 22-23 2018

High Risk Drinking and Prescription Drug Misuse: Relationship with Suicidal Ideation among US National Guard Soldiers by **F. C. Blow, R. V. Ignacio, R. McCormick, M. A. Walton, A. S. B. Bohnert, M. A. Ilgen**. Poster presented at *2^o World Congress of the World Association on Dual Disorders (WADD)*, Florence, October 25-27 2018

Naturalistic Follow-up in Bipolar Patients after Successful Electroconvulsive Therapy by **M. Novi, M. Barbuti, B. Tripodi, A. Boccolini, G. Gemmellaro, F. De Dominicis, C. Elefante, L. Lattanzi, P. Medda, and G. Perugi**. Poster presented at *Neurodevelopmental Psychopathology in Adults: Depressive, Bipolar, Psychotic and Substance Use Disorders*, Pisa, Italy, EU, July, 8-9 2019

High therapeutic buprenorphine levels reduce i.v. fentanyl respiratory depression by **M. G. Tocco, K. Wiest, M. H. Algera, L. Moss, M. van Velzen, G. J. Groeneveld, J. Heuberger, A. Dahan, F. Gray, S. Strafford, R. Dobbins**. Poster presented at *14th EUROPAD European Congress*, Grenoble, France, November 19-21, 2021



CHIMERA AWARD

European Opiate Addiction Treatment Association Award

"The Alessandro Tagliamonte Award"



"Dedicated to all those who dream of a better world for drug addicts"

FORMER RECIPIENTS:

Marc Auriacombe (France) - 2002
Olof Blix (Sweden) - 2000
Miguel Casas (Spain) - 2012
Thomas Clausen (Norway) - 2014
Pascal Courty (France) - 2012
Jean-Jacques Deglon (Switzerland) - 2004
Maurice Dematteis (France) - 2018
Sergey Dvoryak (Ukraine) - 2010
Gabriele Fischer (Austria) - 2008
Gilberto Gerra (Italy) - 2006
Ante Ivancic (Croatia) - 2006
Alexander Kantchelov (Bulgaria) - 2004
Andrej Kastelic (Slovenia) - 2008
Mercedes Lovrecic (Slovenia) - 2002
Angelo G. I. Maremmani (Italy) - 2021
Vladimir Mendelevich (Russia) - 2014
Genci Mucollari (Albania) - 2021
Lubomir Okruhlica (Slovak Republic) - 2002
Matteo Pacini (Italy) - 2018
Pier Paolo Pani (Italy) - 2004
Luis Patricio (Portugal) - 2010
Einat Peles (Israel) - 2016
Slavko Sakoman (Croatia) - 2010
Lorenzo Somaini (Italy) - 2014
Marta Torrens (Spain) - 2006
Didier Touzeau (France) - 2008
Ambros Uchtenhagen (Switzerland) - 2016
Peter Vossenbergh (The Netherlands) - 2016
Helge Waal (Norway) - 2012
Stephan Walcher (Germany) - 2021
Gabrielle Welle-Strand (Norway) - 2018

FORMER CAREER AWARD RECIPIENTS:

Jean-Pierre Daulouede (France) - 2016
Loretta Finnegan (USA) - 2010
Mary Jeanne Kreek (USA) - 2014
Herman Joseph (to memory - USA) - 2021
Joyce Lowinson (USA) - 2007
Icro Maremmani (Italy) - 2004
Robert Newman (USA) - 2012
Marc Reisinger (Belgium) - 2004
Mark Parrino (USA) - 2018
Alessandro Tagliamonte (Italy) - 2004

PLATINUM SPONSORS

Camurus

Indivior

Molteni

SILVER

G. L. Pharma

camurus®



INDIVIOR

Focus on you.



GEROT

LAMINACH

Under the Patronage of

World Federation for the Treatment of Opioid Dependence,
New York, NY, USA



World Federation for the
Treatment of
Opioid Dependence

NGO with Special Consultative Status with United Nations Economic and Social Council (ECOSOC)